- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Ocrelizumab – November 2017
Ocrelizumab: Solution concentrate for I.V. infusion 300 mg in 10 mL; Ocrevus®
Last updated
16 March 2018